10-K: Caring Brands Reports Significant 2025 Loss Amidst IPO and Product Relaunches

Caring Brands, Inc. reported a substantial net loss of $6.28 million for 2025, despite completing an initial public offering and advancing its wellness product pipeline.

Summary

• Caring Brands, Inc. is a wellness consumer products company offering OTC and cosmetic products, including hair loss treatments, eczema/psoriasis solutions, vitiligo treatments, and suncare.
• The company reported nominal revenues of $4,215 and a net loss of $6,278,191 for the year ended December 31, 2025.
• Operating expenses significantly increased to $5,937,367 in 2025, up from $1,525,787 in 2024, driven by higher payroll, professional service fees, and intellectual property amortization.
• An impairment loss of $2,550,000 on intellectual property was recognized in 2025, reducing its carrying value to zero.
• Cash and cash equivalents increased to $2,189,232 as of December 31, 2025, primarily due to net proceeds of $3,235,692 from an initial public offering in November 2025.
• The Hair Enzyme Booster (JW-700) was launched on Amazon in October 2024 and NOVODX's e-commerce platform in December 2024, with minimal initial sales.
• Photocil, a vitiligo and psoriasis treatment, is targeted for a U.S. relaunch in 2026, having been removed from the U.S. market in February 2023 due to insufficient sales.
• CB-101, an eczema treatment, is undergoing reformulation, expected to complete in Q4 2025/Q1 2026, with an anticipated U.S. online launch in Q2 2026.
• The company identified material weaknesses in its internal controls over financial reporting related to period-end financial disclosure, reporting processes, and related party transaction identification.
• Subsequent to year-end, the company completed a private investment in public equity (PIPE) financing of approximately $3.6 million gross proceeds, involving Series A Convertible Preferred Stock and warrants.
• A significant portion of the PIPE proceeds, approximately $3.075 million, was used to repurchase 6,250,000 shares of common stock from insiders, including the CEO, Chairman's entity, and NovoDX.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to significant financial losses, substantial asset impairments, and a 'going concern' warning, despite recent capital raises and product development efforts. The use of PIPE proceeds for insider share repurchases also raises concerns.

Positives

• Successfully completed an initial public offering in November 2025, raising net proceeds of $3,235,692, significantly increasing cash reserves.
• Secured a license agreement with Taisho Pharmaceutical Co., Ltd. for the Hair Enzyme Booster (JW-700) in Japan, with commercial launch expected in 2025, including milestone payments and a 3% royalty.
• Hair Enzyme Booster (JW-700) has two granted U.S. patents and five pending, with clinical studies showing a 124% increase in SULT1A1 activity in one trial and 75% hair regrowth response rate in another.
• Photocil has demonstrated significant efficacy in clinical trials for vitiligo (28% achieved 70% re-pigmentation) and psoriasis (43% achieved complete clearance), with highly statistically significant results (p<0.0001).
• The global psoriasis treatment market was valued at approximately $34 billion in 2023, with the U.S. accounting for 78% of sales and growing at an 18% CAGR, indicating substantial market opportunity.
• The global vitiligo treatment market is projected to grow from $538.90 million in 2024 to $807.70 million by 2034, with the Asia Pacific region, including India, expected to see the fastest growth.
• Management believes existing cash resources are sufficient to fund operations for at least the next twelve months.
• Adopted a Clawback Policy in compliance with SEC and Nasdaq rules, reinforcing accountability.

Negatives

• Incurred a substantial net loss of $6,278,191 for the year ended December 31, 2025, significantly higher than the $1,517,431 loss in 2024.
• Reported nominal revenues of $4,215 in 2025, indicating very early stages of commercialization and limited product sales.
• Recognized a $2,550,000 impairment loss on intellectual property in 2025, writing down its carrying value to zero, reflecting concerns about recoverability.
• Recorded a $500,000 impairment loss on investment in NovoDX in 2025 due to a decline in estimated fair value and uncertainties.
• The company has a limited operating history and a working capital deficiency, raising substantial doubt about its ability to continue as a going concern.
• Photocil was removed from the U.S. market in February 2023 due to insufficient sales and lack of a dedicated sales and marketing team.
• Sales of the Hair Enzyme Booster (JW-700) have been minimal during its initial soft launch period on Amazon and NOVODX's e-commerce platform.
• Identified material weaknesses in internal controls over financial reporting, specifically ineffective controls over period-end financial disclosure and related party transaction identification.
• A significant portion of the net proceeds from a post-period PIPE financing ($3.075 million out of $3.6 million gross) was used to repurchase shares from insiders, which could be viewed negatively by external investors.

Risks

• Limited operating history makes it difficult to accurately evaluate business prospects and forecast future revenues.
• Financial situation creates substantial doubt about the company's ability to continue as a going concern, dependent on generating revenue or obtaining additional financing.
• Inability to keep up with rapid technological changes could render products obsolete.
• May not have adequate capital to fund the business and may be unable to raise needed additional capital or financing on acceptable terms.
• Intense competition in the skin care and hair growth product markets from larger, better-resourced companies.
• Failure to develop and maintain brand and reputation could materially harm business and prospects.
• Heavy dependence on key personnel, and turnover of senior management could harm the business.
• Subject to government regulation, and unfavorable changes could substantially harm business and results of operations.
• Products may not meet health and safety standards or could become contaminated, leading to recalls and liability claims.
• The sale of products involves product liability and related risks that could expose the company to significant insurance and loss expenses.
• Success depends on the ability to create and expand brand awareness in highly competitive markets with advertising and labeling limitations.
• Must develop and introduce new products to succeed, with success dependent on sales/marketing, timely delivery, raw material availability/pricing, regulatory allowance, and customer acceptance.
• Adverse publicity associated with products or ingredients could adversely affect sales and revenue.
• No products on the market have been approved by the FDA for the treatment of disease, and obtaining such approvals is expensive, lengthy, and uncertain.
• Limited experience in completing regulatory filings could lead to delays or rejections.
• Serious adverse or undesirable side effects identified during product development could lead to abandonment or limitation of commercialization.
• Delays or difficulties in enrolling subjects in clinical trials could delay or prevent regulatory approvals.
• Inability to manufacture products in sufficient quantities or at defined quality specifications, or obtain regulatory approvals for manufacturing facilities, could hinder development and market demand.
• Uncertainty whether product liability insurance will be adequate or affordable in the future.
• Market opportunities for current and potential future drug candidates may be smaller than believed.
• Inability to establish relationships with licensees or collaborators for sales, marketing, and distribution functions could prevent successful product marketing.
• Commercial success of OTC/Cosmetic product candidates depends on acceptance by physicians, payers, and patients.
• Subject to various federal and state fraud and abuse laws if FDA approval for product candidates is obtained, potentially increasing operating costs and legal risks.
• Natural disasters and other events beyond control could materially adversely affect the company.
• May not meet product development and commercialization milestones.
• Operations in international markets involve inherent risks, including macroeconomic conditions, foreign currency exchange rates, political instability, and regulatory differences.
• May be unable to achieve some or all of the benefits expected from the separation from Safety Shot.
• Limited operating history as a publicly traded company, and historical financial information may not be representative of future results.
• May not be able to access credit and capital markets at the times and in the amounts needed on acceptable terms.
• Insurance maintained may not fully cover all potential exposures.
• Conflicts of interest due to directors and executive officers owning Safety Shot common stock or holding positions with Safety Shot.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights to technologies.
• Potential for rapid growth and entry into new markets makes it difficult to evaluate business prospects and manage growth effectively.
• Changes in tax laws and unanticipated tax liabilities could adversely affect the effective income tax rate and ability to achieve profitability.
• May incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.
• Inability to protect intellectual property rights could reduce the value of products and brands.
• Intellectual property behind products may include unpublished know-how dependent on key individuals, and all intellectual property protection eventually expires.
• Reduced disclosure requirements applicable to emerging growth companies may make common stock less attractive to investors.
• Requirements of being a public company may strain resources and distract management.
• Management has limited experience in managing day-to-day operations of a public company, potentially incurring additional expenses.
• Compliance with changing corporate governance regulations and public disclosures may result in additional risks and exposures.
• Certain stockholders hold a significant percentage of voting securities, which could reduce the ability of minority stockholders to effect corporate actions.
• Inaccurate or unfavorable research by securities or industry analysts could cause stock price to decline.
• Issuance of additional common stock or preferred stock may cause common stock price to decline.
• Common stock may become subject to SEC's penny stock rules, adversely affecting trading activity.
• Market price of securities may be volatile, causing investment value to decline.
• May not be able to satisfy listing requirements of NASDAQ or obtain or maintain a listing.
• Do not intend to pay dividends for the foreseeable future.
• Sales of a substantial number of shares of common stock in the public market could cause stock price to fall.
• Anti-takeover provisions in the company's charter and bylaws may prevent or frustrate attempts by stockholders to change the board or management.

Future Outlook

The company plans to relaunch Photocil in the U.S. in 2026 and anticipates completing the reformulation of CB-101 in Q4 2025/Q1 2026, with an online U.S. launch in Q2 2026. It expects Taisho to commercially launch the Hair Enzyme Booster in Japan in 2025. The company intends to seek acquisition opportunities in the branded consumer products space and expand its online retail strategies. Management believes existing cash resources are sufficient to fund operations for at least the next twelve months but may seek additional capital for long-term growth, strategic investments, or acquisitions.

Management Comments

• Management believes that phototherapy treatments, used for conditions such as psoriasis and vitiligo, are set for substantial growth globally.
• Management believes that Psoriasis treatment with Photocil may only address a very small fraction of the market in the US and India.
• Management believes India presents a potential opportunity for market expansion for vitiligo treatments.
• Management believes that Vitiligo treatment with Photocil is expected to address only a very small fraction of the total global market.
• Management believes our relations with our employees to be good.
• Management believes that existing cash resources are sufficient to fund operations for at least the next twelve months.

Industry Context

StockSavvy.ai notes that Caring Brands operates in the highly competitive wellness consumer products industry, specifically targeting the skin care and hair growth markets. The global phototherapy treatment market is projected to grow from ~$1.9 billion in 2023 to ~$3.23 billion by 2033 (CAGR 5.2%), with India's market expanding faster at ~7.8% CAGR. The global psoriasis treatment market was worth ~$34 billion in 2023, with the U.S. dominating at 78% market share and an 18% CAGR. The global vitiligo treatment market was valued at ~$538.90 million in 2024, projected to reach ~$807.70 million by 2034 (CAGR 4.60%). While these market trends indicate significant opportunities, Caring Brands faces challenges in capturing market share against larger, established competitors, especially given its limited operating history and nominal revenues.

Comparison to Industry Standards

• The global psoriasis treatment market, valued at approximately $34 billion in 2023, is dominated by biologics like IL-23 inhibitors (e.g., Skyrizi, Tremfya) and IL-17 inhibitors (e.g., Taltz, Cosentyx), which hold significant market share (31% and 23% respectively). Caring Brands' Photocil, a topical narrow-band UV filter, offers a different approach with minimal side-effects compared to these biologics, which can have significant side-effects including increased susceptibility to infections and cardiovascular risks.
• For vitiligo, Ruxolitinib (Opzelura) by Incyte is the only FDA-approved biologic. Photocil offers a more convenient topical treatment with fewer side effects compared to conventional phototherapy or corticosteroids.
• The Hair Enzyme Booster (JW-700) is designed to improve the efficacy of minoxidil, an FDA-approved treatment for hair growth, in a market valued at over $1 billion worldwide in 2024. This positions it differently from many nutritional supplements that address hair growth but are not FDA approved or clinically proven to enhance minoxidil's action.
• The company's licensing agreement with Taisho Pharmaceutical Co., Ltd., Japan's leading seller of minoxidil products, suggests a strong validation of the Hair Enzyme Booster's potential in a key market, indicating a strategic alignment with an established industry player.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any legal or administrative proceedings.
• No pending litigation or proceeding involving any directors or officers as to which indemnification is required or permitted, and no awareness of any threatened litigation.

Related Party Transactions

• Safety Shot, Inc. (former parent and current significant shareholder) waived an outstanding balance of $275,876 owed by Caring Brands Florida at September 24, 2024, treating it as additional paid-in capital.
• In June and July 2025, the Company entered into short-term loans with CEO Dr. Glynn Wilson ($50,000) and Chairman Brian John ($25,000) at an 8% interest rate, both repaid by December 31, 2025.
• In May 2024, NOVODX Corporation (a related party, whose CEO was a former director of Caring Brands) acquired 500,000 shares of the Company's common stock for $500,000.
• In June 2024, the Company invested $500,000 in NOVODX's private placement, purchasing 25,134 shares (less than 1% ownership).
• On June 20, 2024, the Company entered into a Research Collaboration and Non-Exclusive License Agreement with NOVODX, issuing 3,000,000 shares of restricted common stock, which was later terminated on March 10, 2026.
• During 2024, Safety Shot paid $78,980 in operating expenses on behalf of the Company, which Safety Shot later waived in 2025, recognized as a capital contribution.
• On November 6, 2025, the Company entered a short-term loan agreement with Caro Partners (an entity related to Brian John) for $45,000, which was repaid on November 19, 2025.
• Subsequent to year-end, on March 19, 2026, the Company agreed to repurchase 1,500,000 shares from Dr. Glynn Wilson for $750,000 cash.
• Subsequent to year-end, on March 19, 2026, the Company agreed to repurchase 1,250,000 shares from BK Investments LLC (owned by Brian John) for $1,250,000 cash.
• Subsequent to year-end, on March 19, 2026, the Company agreed to repurchase 3,500,000 shares from NovoDX, Inc. for $1,075,000 cash, as part of a settlement agreement.

Stakeholder Impact

• Shareholders: Face significant dilution risk from future capital raises and potential stock price volatility due to the company's limited operating history, substantial losses, and 'going concern' doubt. The post-period share repurchases from insiders using PIPE proceeds could be viewed negatively by external shareholders.
• Employees: The company has three full-time employees, including key management. The significant increase in payroll expenses in 2025 suggests expansion, but the overall financial instability could pose job security concerns.
• Customers: Product availability and marketing efforts are in early stages, with some products like Photocil having been removed from the U.S. market previously. Future product launches and marketing strategies will determine customer adoption and satisfaction.
• Creditors: The company has outstanding debt, including a term loan and related party loans (some repaid). The 'going concern' warning indicates increased risk for creditors, although the recent IPO and PIPE have improved short-term liquidity.
• Suppliers: The company relies on third-party manufacturers and multiple raw material vendors. Supply chain disruptions or financial instability could impact relationships and product availability.

Next Steps

• Relaunch Photocil in the United States, targeted for 2026, exploring manufacturing and marketing options.
• Apply for a National Drug Code (NDC) number for FDA registration of Photocil prior to its U.S. relaunch.
• Complete reformulation of CB-101 eczema treatment in Q4 2025/Q1 2026.
• Make CB-101 available online in the U.S. in Q2 2026 as an over-the-counter product under a USP monograph.
• Plan to apply for FDA registration and an NDC number for CB-101 prior to marketing.
• Taisho Pharmaceutical Co., Ltd. expects to commercially launch the Hair Enzyme Booster (JW-700) in Japan in 2025.
• Explore additional sub-licensing opportunities for Photocil in Nepal, Bangladesh, Sri Lanka, Vietnam, Philippines, Malaysia, Cambodia, Laos, Indonesia, UAE, Egypt, Algeria, Tunisia, Congo, Nigeria, Kenya, Thailand, Bahrain, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, and Saudi Arabia.
• Engage in preliminary discussions regarding potential licensing opportunities for Photocil in Europe and South America.
• Explore the possibility of engaging DCR Labs to manufacture CB-101 in the future.
• Continually update and expand the corporate website (CaringBrands.com) and refine online retail strategies.
• Build e-commerce websites dedicated to each brand and a website for wholesale/distributor clients.
• Seek acquisition opportunities in the branded consumer products space, including additional OTC/cosmetic therapeutic and skin care brands.
• Implement and maintain enhanced controls and formalize the internal control environment to remediate identified material weaknesses.

Key Dates

Recommendation

The company's financial position is highly precarious, marked by substantial and increasing net losses, nominal revenues, and a clear 'going concern' warning from its auditors. The significant impairment of intellectual property and investment assets indicates a write-down of core value. While the recent IPO and PIPE financing provide short-term liquidity, a large portion of the PIPE proceeds was used for insider share repurchases, which is often viewed unfavorably by external investors as it suggests a lack of confidence from insiders in the company's future growth or an unfavorable use of capital. The identified material weaknesses in internal controls further compound the risk profile. Given the limited operating history, intense competition, regulatory uncertainties, and the company's inability to generate meaningful revenue, the investment carries an exceptionally high risk of capital loss. A seasoned investor would likely recommend selling to avoid further downside exposure until there is clear evidence of sustainable revenue generation, profitability, and remediation of internal control deficiencies.

Keywords

Wellness Consumer Products, OTC Products, Cosmetic Products, Hair Loss Treatment, Eczema Treatment, Psoriasis Treatment, Vitiligo Solutions, Jellyfish Sting Protection, Suncare, SEC Filing, 10-K, Financial Reporting, Public Company, NASDAQ, Intellectual Property, Clinical Trials, FDA Regulation, Going Concern, Capital Raise, Insider Transactions